|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||19.75 - 19.75|
|52 Week Range||8.65 - 20.50|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Eurofins Scientific (EUFI.PA), a global scientific leader in bioanalytical testing announces the acquisition of Beacon Discovery, a preeminent drug discovery and contract research organization (CRO) focused on G-Protein Coupled Receptor (GPCR) research. Beacon Discovery joins Eurofins Discovery, a market leading CRO with the broadest portfolio of validated in vitro pharmacology, ADMET*, and chemistry services for integrated drug discovery solutions. The transaction is expected to close in the coming weeks upon fulfilment of customary closing conditions.
Eurofins adds today virus variant monitoring capabilities to its commercially available SARS-CoV-2 stand-alone test kit portfolio. This new solution is also part of the Eurofins Covid-19 Sentinel™ and the SAFER@WORK™ program which provide an early warning of the presence of SARS-CoV-2 amongst large populations at a given site (e.g. a city, factories, education institutions, government and public service sites, nursing homes), before the virus spreads too broadly.
Eurofins Scientific, a global scientific testing Group has brought together its UK laboratories across multiple disciplines to work together to facilitate increased direct to consumer COVID-19 testing, significantly increasing the UK’s current testing capacity.